Clinical trials: Ritonavir
HIV Infections
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.
- Trial name
- NCT00135343
- Testing
- Atazanvir/ritonavir + efavirenz
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva
In the pre-partum phase the use of antiretroviral therapy for the mother during the last trimester of pregnancy is mandatory. The use of HAART during pregnancy, usually two nucleosides analogues and a protease inhibitor exposes…
- Trial name
- NCT00424814
- Testing
- Kaletra (lopinavir/ritonavir), Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Corona Virus Infection, COVID-19
Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia
In-vitro studies revealed that nafamostat mesylate has antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-inflammatory and anti-coagulation effect.
- Trial name
- NCT04418128
- Testing
- Nafamostat Mesylate
- Volunteers
- 84 people
- Sponsor
- Gyeongsang National University Hospital
HIV Seropositivity
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
The goal of this phase II, open-label, randomized, controlled clinical trial is to evaluate the impact of Gammora®, a 16-mer HIV integrase-derived peptide associated with a boosted darunavir antiretroviral regimen compared…
- Trial name
- NCT06799650
- Testing
- Gammora®
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
Hepatitis C
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve…
- Trial name
- NCT01467479
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 59 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Infections
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
The ANRS 12174 study is a clinical trial that will compare the efficacy and safety of prolonged infant peri-exposure prophylaxis (PEP) with Lopinavir/Ritonavir (LPV/r) versus Lamivudine to prevent HIV-1 transmission through…
- Trial name
- NCT00640263
- Testing
- lopinavir/ritonavir (LPV/r), Lamivudine (3TC)
- Where
- 4 sites in Burkina Faso, South Africa and 2 more
- Volunteers
- 1,500 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
To determine the short-term virologic and immunologic effects of using plasma genotypic antiretroviral resistance testing (GART) results (interpreted by study virologists AS PER AMENDMENT 9/17/97) in the management of therapy for…
- Trial name
- NCT00000874
- Where
- 24 sites in United States
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Once-Daily Drug Regimen for HIV-Infected Patients
This study will examine the safety of giving antiviral therapy for HIV infection in a once-daily dosing schedule, and assess how well patients tolerate this regimen.
- Trial name
- NCT00001968
- Testing
- Amprenavir, Ritonavir, Abacavir
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement…
- Trial name
- COLCOVID (NCT04328480)
- Testing
- Colchicine, Local standard of care
- Where
- Argentina
- Volunteers
- 1,279 people
- Sponsor
- Estudios Clínicos Latino América
HIV Infection
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV-infected people who have never received anti-HIV therapy be treated with a triple drug regimen (commonly called combination antiretroviral…
- Trial name
- NCT00851799
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir
- Where
- 26 sites in United States
- Volunteers
- 334 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HCV Coinfection
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus…
- Trial name
- NCT03549832
- Testing
- Sofosbuvir, Simeprevir, Daclatasvir
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
HIV Infections
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
For participants with HIV taking either lopinavir or fosamprenavir who have elevated triglycerides, this trial will study the change in triglycerides after switching protease inhibitors.
- Trial name
- LARD (NCT00756730)
- Testing
- ATV/r, DRV/r
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Community Research Initiative of New England
HIV Infections, Acquired Immunodeficiency Syndrome
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
The purpose of this study is to determine the pharmacokinetics (how the body absorbs, distributes, metabolizes and eliminates a drug) (PK) of ETR when given with ATV/rtv and 1 NRTI in treatment experienced HIV-1 infected…
- Trial name
- NCT00896051
- Testing
- Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 50 people
- Sponsor
- Janssen R&D Ireland
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Chronic Hepatitis C Virus
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in…
- Trial name
- NCT02945228
- Where
- 170 sites in Japan
- Volunteers
- 449 people
- Sponsor
- AbbVie
HIV Infections
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtide-based combination therapy)
- Trial name
- EASIER (NCT00454337)
- Testing
- FTC/TDF + EFV or LPV/R +T20, FTC/TDF + EFV or LPV/R
- Where
- France
- Volunteers
- 170 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Atazanavir/Ritonavir Maintenance Therapy
Long-term side effects, the expense of medications, and the difficulty of taking medications continuously for long periods of time are all problems with complicated anti-HIV drug regimens.
- Trial name
- NCT00084019
- Testing
- Atazanavir, Ritonavir
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or…
- Trial name
- FLAMINGO (NCT01449929)
- Testing
- dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
- Where
- 66 sites in United States, France and 7 more
- Volunteers
- 488 people
- Sponsor
- ViiV Healthcare